NICE set to extend MabThera recommendation PMLiVE Final draft guidance from the National Institute for Health and Care Excellence (NICE) recommends MabThera (rituximab) be available for use on the NHS to treat severe forms of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). UK's NICE gives green light to Roche's MabThera for GPA and MPA |
